Clinical trial
A First-in-human Research Study on How NNC0721-8060 Works in People Living With Overweight or Obesity
Recruiting now · Phase 1 · 1 countries · Registry ID NCT07767175
Recruiting nowPhase 1Interventional
What this study is about
The purpose of the study is to find out if NNC0721-8060 is safe and how it works in people living with overweight or obesity.
A promising-looking record is not the same as confirmed eligibility. The study team must review the full criteria and current recruitment status.
Basic eligibility
Age18 Years to 55 Years
SexAll
Healthy volunteersAccepted
ConditionOverweight, Obesity
Full registry criteria
Inclusion Criteria: * Male or female (sex at birth). * Age 18-55 years (both inclusive) at the time of signing informed consent. * Body Mass Index (BMI) 27.0-34.9 kilograms per square metre (kg/m\^2) (both inclusive) at screening, with overweight due to excess adipose tissue as judged by the investigator. * Considered eligible based on medical history, physical examination, vital signs, electrocardiogram and clinical laboratory tests at screening, as judged by the investigator. Exclusion Criteria: * Known or suspected hypersensitivity to study intervention(s) or related products. * Previous randomisation in this study. * History of allergies (with the exception of seasonal allergies) or history of anaphylactic reactions. * Female who is pregnant, breastfeeding, intends to become pregnant, or is of childbearing potential and not using adequate contraception. * Current participation (signed informed consent) in any other interventional clinical study. * Exposure to an investigational medicinal product within 30 days or five half-lives of that product (whichever is longer) before screening. * Any disorder, unwillingness or inability which, in the investigator's opinion, might jeopardise participant safety or compliance with the protocol. * Glycated haemoglobin (HbA1c) greater than or equal to (≥) 6.5 percentage (%) (48 millimoles per mole \[mmol/mol\]) at screening.
Treatments and study arms
NNC0721-8060
Drug
NNC0721-8060 will be administered subcutaneously.
Semaglutide
Drug
Semaglutide will be administered subcutaneously.
Placebo
Drug
Placebo will be administered subcutaneously.
Primary outcomes
Part A: Number of treatment emergent adverse events (TEAE)From Day 1 to Day 36
Measured as number of events.
Part B: Number of treatment emergent adverse events (TEAE)From Day 1 to Day 57
Measured as number of events.
Part C: Change from baseline in body weightFrom Day 1 to Day 85
Measured as percentage change in body weight.